Log In
BCIQ
Print this Print this
 

sebelipase alfa (Kanuma) (formerly SBC-102)

Also known as: rhLAL

  Manage Alerts
Collapse Summary General Information
Company Alexion Pharmaceuticals Inc.
DescriptionRecombinant human lysosomal acid lipase (LAL) enzyme replacement therapy (ERT)
Molecular Target
Mechanism of ActionEnzyme replacement therapy
Therapeutic ModalityBiologic: Enzyme
Latest Stage of DevelopmentMarketed
Standard IndicationGlycosphingolipid storage disorders
Indication DetailsTreat early onset LAL deficiency (Wolman disease); Treat LAL deficiency (Wolman disease); Treat late onset LAL deficiency (cholesteryl ester storage disease); Treat lysosomal acid lipase (LAL) deficiencies
Regulatory Designation U.S. - Breakthrough Therapy (Treat early onset LAL deficiency (Wolman disease));
U.S. - Fast Track (Treat early onset LAL deficiency (Wolman disease));
U.S. - Orphan Drug (Treat early onset LAL deficiency (Wolman disease));
U.S. - Orphan Drug (Treat LAL deficiency (Wolman disease));
U.S. - Priority Review (Treat LAL deficiency (Wolman disease));
EU - Orphan Drug (Treat LAL deficiency (Wolman disease));
EU - Orphan Drug (Treat early onset LAL deficiency (Wolman disease));
Japan - Orphan Drug (Treat early onset LAL deficiency (Wolman disease));
Switzerland - Orphan Drug (Treat early onset LAL deficiency (Wolman disease));
Switzerland - Orphan Drug (Treat late onset LAL deficiency (cholesteryl ester storage disease))
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

2

$8,788.4M

$4,473.5M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

06/23/2015

$8,788.4M

$4,473.5M

0

11/03/2011

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today